Patient Education
Share your love
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
What if? Curing any eye disease with the snap of your finger
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Celltrion announces phase 3 trial data for EYDENZELT
(Image credit: ©HockleyM2) Celltrion recently announced 52-week findings from its global phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT.1 EYDENZELT, a biosimilar of EYLEA (aflibercept), is Celltrion’s ophthalmic treatment candidate for the treatment of multiple retinal diseases, including…
Hispanic patients with POAG had lower success rates after glaucoma surgery compared with patients of European descent
(Image credit: AdobeStock/Vladislav) A study reported lower success rates associated with initial trabeculectomy with mitomycin C (MMC) in Hispanic patients compared with those who were of European descent. This information may be useful when considering patient candidacy for glaucoma surgery,1…
Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series
Kicking off Northwestern University’s “Dinner with the Experts” series, Angelo P. Tanna, MD, leads a deep dive into OCT and perimetry for glaucoma progression on September 9, 2025. (Image credit: AdobeStock/FourLeafLover) As part of its new “Dinner with the Experts…
Alcon completes acquisition of LumiThera
(Image Credit: AdobeStock/Timon) Alcon has completed its planned acquisition of LumiThera, Inc, which was announced earlier in July of this year.1,2 According to Alcon, the acquisition includes the noninvasive Valeda photobiomodulation (PBM) device for the treatment of early and intermediate dry…
Inside Northwestern University’s “Dinner with the Experts” educational series with Robert S. Feder, MD
The Northwestern University Department of Ophthalmology is launching “Dinner with the Experts – Cases, Updates, and Clinical Pearls,” a collaborative space for sharing ophthalmic knowledge and practical takeaways. (Image credit: AdobeStock/Harsha) The Northwestern University Department of Ophthalmology is launching a…
Ashvattha reports positive phase 2 results for migaldendranib in DME and nAMD
(Image Credit: AdobeStock) Ashvattha Therapeutics shared positive topline data from its phase 2 study of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The topline end-of-study results were announced at the 25th…
Contivue port delivery platform for nAMD receives CE mark
(Image credit: ©Symbiot/AdobeStock) The European Union has granted the EU CE mark to Roche’s port delivery platform, Contivue.1 This platform contains Susvimo (ranibizumab injection) 100 mg/mL, which is currently under review with the European Medicines Agency (EMA) for the treatment…
Creation of OpZira Inc. announced following Alcon’s acquisition of LumiThera
(Image credit: AdobeStock) The company OpZira Inc. has launched to advance ophthalmic diagnostics. The company plans to deliver innovative technologies with the ability to enhance the detection and monitoring of ocular disease, which can empower clinicians. Clark Tedford, PhD, President…